Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21628-21635

  Inamoto, Teruo ^a   Taniguchi, Kohei ^b   Takahara, Kiyoshi ^a   Iwatsuki, Ayako ^b   Takai, Tomoaki ^a   Komura, Kazumasa ^a   Yoshikawa, Yuki ^a   Uchimoto, Taizo ^a   Saito, Kenkichi ^a   Tanda, Naoki ^a   Kouno, Junko ^a   Minami, Koichiro ^a   Uehara, Hirofumi ^a   Hirano, Hajime ^a   Nomi, Hayahito ^a   Kiyama, Satoshi ^a   Akao, Yukihiro ^b   Azuma, Haruhito ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Intravesical instillation; microRNA 145

Indexed keywords

BETA CATENIN; CATENIN; CATENIN DELTA 1; MICRORNA 145; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; UVOMORULIN; MICRORNA; MIRN145 MICRORNA, HUMAN;

253J B V CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; BLADDER WALL; CANCER CONTROL; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR XENOGRAFT; ANIMAL; BLADDER TUMOR; CANCER TRANSPLANTATION; CELL LINE; CELL MOTION; DRUG SCREENING; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ADMINISTRATION, INTRAVESICAL; ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION; TRANSFECTION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940750339     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4129     Document Type: Article

References (22)

1. Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS, Urologic Diseases in America P. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013; 119: 3219-27.
2. Kamatani A, Nakagawa Y, Akao Y, Maruyama N, Nagasaka M, Shibata T, Tahara T, Hirata I. Downregulation of anti-oncomirs miR-143/145 cluster occurs before APC gene aberration in the development of colorectal tumors. Medical molecular morphology. 2013; 46: 166-71.
3. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, Nakashima R, Kitade Y, Naoe T. Role of anti-oncomirs miR-143 and-145 in human colorectal tumors. Cancer gene therapy. 2010; 17: 398-408.
4. Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and-145 in colon cancer. DNA and cell biology. 2007; 26: 311-20.
5. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and-145 in human gastric cancers. Oncology. 2009; 77: 12-21.
6. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and-145 in B-cell malignancies. Cancer science. 2007; 98: 1914-20.
7. Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncology reports. 2006; 16: 845-50.
8. Noguchi S, Mori T, Hoshino Y, Yamada N, Nakagawa T, Sasaki N, Akao Y, Maruo K. Comparative study of anti-oncogenic microRNA-145 in canine and human malignant melanoma. The Journal of veterinary medical science/the Japanese Society of Veterinary Science. 2012; 74: 1-8.
9. Yamada N, Noguchi S, Mori T, Naoe T, Maruo K, Akao Y. Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells. Cancer letters. 2013; 335: 332-42.
10. Noguchi S, Yasui Y, Iwasaki J, Kumazaki M, Yamada N, Naito S, et al. Replacement treatment with microRNA-143 and-145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer letters, 2013 ; Jan 28;328(2):353-361.
11. Noguchi S, Yamada N, Kumazaki M, Yasui Y, Iwasaki J, Naito S, Akao Y. socs7, a target gene of microRNA-145, regulates interferon-beta induction through STAT3 nuclear translocation in bladder cancer cells. Cell death & disease. 2013; 4: e482.
12. Iio A, Nakagawa Y, Hirata I, Naoe T, Akao Y. Identification of non-coding RNAs embracing microRNA-143/145 cluster. Molecular cancer. 2010; 9: 136.
13. Akao Y, Khoo F, Kumazaki M, Shinohara H, Miki K, Yamada N. Extracellular disposal of tumor-suppressor miRs-145 and-34a via microvesicles and 5-FU resistance of human colon cancer cells. International journal of molecular sciences. 2014; 15: 1392-401.
14. Black PC, Brown GA, Dinney CP, Kassouf W, Inamoto T, Arora A, Gallagher D, Munsell MF, Bar-Eli M, McConkey DJ, Adam L. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. The Journal of urology. 2011; 185: 693-700.
15. Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Molecular cancer therapeutics. 2008; 7: 3825-33.
16. Kumazaki M, Noguchi S, Yasui Y, Iwasaki J, Shinohara H, Yamada N, Akao Y. Anti-cancer effects of naturally occurring compounds through modulation of signal transduction and miRNA expression in human colon cancer cells. The Journal of nutritional biochemistry. 2013; 24: 1849-58.
17. Fahmy M, Mansure JJ, Brimo F, Yafi FA, Segal R, Althunayan A, Hicks J, Meeker A, Netto G, Kassouf W. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Human pathology. 2013; 44: 1766-72.
18. Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, Bohle A. Current clinical practice gaps in the treatment of intermediate-and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS). BJU international. 2013; 112: 742-50.
19. Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guerin treatment failure. The Journal of urology. 2013; 190: 1686-91.
20. Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, Matsumura Y. Exosome can prevent RNase from degrading microRNA in feces. Journal of gastrointestinal oncology. 2011; 2: 215-22.
21. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26: 3291-310.
22. Mizuno R, Kamioka Y, Kabashima K, Imajo M, Sumiyama K, Nakasho E, Ito T, Hamazaki Y, Okuchi Y, Sakai Y, Kiyokawa E, Matsuda M. In vivo imaging reveals PKA regulation of ERK activity during neutrophil recruitment to inflamed intestines. The Journal of experimental medicine. 2014; 211: 1123-36.